Sanofi will use the artificial intelligence to drive the platform to develop bispecific drugs
On May 9, according to the GEN website, Sanofi and Exscientia signed a cooperation and licensing transaction with a potential value of 250 million euros (about 276 million US dollars). The deal aims to develop bispecific small molecule drugs for metabolic diseases. Exscientia will use its artificial intelligence (AI)-driven platform and automated design capabilities to identify synergistic drug target combinations and then use its lead-finding platform to identify bispecific small targets for these targets. Molecular drugs. Exscientia will be responsible for all compound designs and Sanofi offers chemical synthesis. In addition, Sanofi retains the option to license "related compounds" and will undertake future preclinical and clinical development. Exscientia will receive research funding for identifying "target pairs" and priority drug candidates and will be eligible for future non-clinical, clinical, and sales-related milestone payments. Exscientia's drug development "engine" is built on an AI platform. Companies can use the platform to design and evaluate new compounds, including potency, selectivity, and ADME. The company is using the platform to build partnerships to develop small molecule drugs for single targets and bispecific small molecule candidates for target combinations. Hydraulic Power Unit,Hydraulic Pump Unit,Hydraulic Power Station,Power Unit,Hydraulic Poppet Valve,Hydraulic Pilot Valve Changzhou Satidi Import and Export Co., Ltd. , https://www.guanjiejts.com